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Abstract 
Background: In this descriptive study of male and female mice at different weeks of age, we use serial non-invasive 
cardiac 18F-FDG-PET scans to follow up on metabolic alterations, heart function parameters, and the ECG of both 
sexes in early to mid-adulthood.
Methods: ECG-gated 18F-FDG-PET scans were performed in mice on 10, 14, and 18 weeks of age, using a dedicated 
small-animal PET scanner. The percentage of the injected activity per gram (%IA/g) in the heart, left ventricular meta-
bolic volume (LVMV), myocardial viability and left ventricular function parameters: end-diastolic (EDV), end-systolic 
(ESV), stroke volume (SV), and the ejection fraction (EF%) were estimated.
Results: Compared to their age-matched female counterpart, male mice showed a constant increase in LVMV and 
ventricular volume during the follow-up. In contrast, female mice remain stable after ten weeks of age. Furthermore, 
male mice showed lower heart rates, positive correlation with cardiac %IA/g, and negative correlation with LVMV.
Conclusion: In this study of serial cardiac PET scans, we provide insight for basic murine research models, showing 
that mice gender and age show distinct cardiac metabolisms. These physiologic alterations need to be considered 
when planning in vivo injury models to avoid potential pitfalls.
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Introduction
Cardiomyopathy, heart failure, and coronary artery dis-
ease are the main reasons for heart diseases being the 
leading causes of death in western society [1]. Fundamen-
tal in  vitro and in  vivo molecular research aims to find 
new translational diagnostics and therapeutic perspec-
tives to lower mortality and improve patients’ quality of 
life. Especially in  vivo animal models are most suitable 
for transferring clinical obstacles, such as myocardial 
infarction due to coronary artery disease into a research 
setting to decipher underlying mechanisms and prevent 
further deteriorating events. For instance, murine mod-
els of myocardial infarction aim to reduce the myocardial 
damage and improve the cardiac remodelling to preserve 
the cardiac function after irreversible loss of heart muscle 
cells.
Standard animal models, including mice, rats, rabbits, 
and pigs, are used to broaden our understanding of dis-
eases. Out of these, mice models are the most common 
due to short reproduction time, comfortable breeding, 
feasible logistics, and costs.
Most of the current cardiac injury models are per-
formed with male mice [2, 3]. Nevertheless, several 
murine studies indicate that cardiovascular injury 
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models, depending on mouse gender, differ in their 
results [4, 5].
For instance, mice deficient of the G-protein coupled 
receptor 30 (GPR30), a membrane-bound estrogen recep-
tor involved in the estradiol signalling, demonstrate that 
male but not female mice develop impaired left-ventricu-
lar cardiac function [6]. The overexpression of the cardiac 
sodium-calcium exchanger increases the susceptibility 
to ischemia–reperfusion injury in male but not female 
mice [7]. In a diabetic mouse model, the induced adverse 
cardiac remodelling was observed earlier in female mice 
than in their male counterparts [8]. These publications 
further state several underlying molecular and functional 
differences in the hearts of male and female mice.
Moreover, mice are used for cardiac injury models at 
different age stages, commonly starting at eight weeks up 
to 18 weeks.
Functional imaging using positron emission tomogra-
phy (PET) facilitates serial non-invasive measurements 
of the same individuum at different time points [9, 10]. 
ECG-gated functional PET imaging with 2-deoxy-2-
[18F]fluoro-D-glucose (18F-FDG) not only enables the 
assessment of cardiac viability but also estimating left 
ventricular function parameters (end-diastolic volume 
(EDV), end-systolic volume (ESV), stroke volume (SV) 
left ventricular ejection fraction (EF%)) [11], as already 
demonstrated in several cardiac stress models, e.g., in 
myocardial infarction model and transaortic constriction 
model for induction of heart hypertrophy [12, 13].
Researchers conduct in vivo studies either in one sex or 
less often distinguish between sexes in laboratory animal 
studies. Besides using various experiment ages for mice, 
there is still a lack of knowledge, for the most suitable 
time frame to perform cardiac injury models and avoid 
growth-dependent biases.
Therefore, this study aimed to evaluate metabolic and 
cardiac function parameters using serial micro PET 
measurements in ageing male and female mice to provide 




Male and female C57/BL6 mice were purchased from 
Charles River (Sulzfeld, Germany). Animal care and all 
experimental procedures were performed according to 
the Guideline for the Care and Use of Laboratory Ani-
mals published by the U.S. National Institutes of Health 
(NIH publication no. 85–23, revised 1996). All animals 
received humane care. Study protocols complied with the 
institution’s guidelines and were approved by the Gov-
ernment’s animal ethics committee.
In vivo cardiac PET imaging
ECG-gated 18F-FDG micro PET scans were performed 
on 10, 14 and 18 weeks of age, using a dedicated small-
animal PET scanner (Inveon Dedicated PET, Preclini-
cal Solutions, Siemens Healthcare Molecular Imaging, 
Knoxville, TN, USA; n = 8 for the male group, n = 8 
for the female group) as described previously [13, 14]. 
The animals had free access to food and water until 
just before the scan, as published previously [10, 11, 
14, 15]. Anaesthesia was induced (2.0–2.5%) and main-
tained (1.5%) with isoflurane delivered in pure oxygen 
at a rate of 1.4 L/min via a face mask. The mice did not 
receive any special pretreatment to enhance the myo-
cardial uptake since it is well known that isoflurane 
anaesthesia leads to a significant myocardial 18F-FDG 
uptake [16–19]. The core body temperature was main-
tained within the normal range using a heating pad 
and monitored by a rectal thermometer. Neonatal ECG 
electrodes (3  M, St. Paul, MN, USA) were placed on 
both forepaws and the left hind paw. After placing an 
intravenous catheter into a tail vein, approx. 20  MBq 
of 18F-FDG was injected in a volume of ~ 100  mL. 
The catheter was then flushed with 50  mL of saline 
solution. Animals remained anaesthetized during the 
entire scan and were placed in prone position within 
the PET tomograph. A three-dimensional PET record-
ing was obtained in list mode lasting from 30–45  min 
after injection of the tracer. For attenuation and scatter 
correction, a 7-min transmission scan was performed 
with a rotating [57Co] source immediately after each 
PET scan, as described previously [12]. Recovery from 
anaesthesia and the PET scan was monitored closely 
in the home cage with a veterinarian monitoring. The 
recorded data were processed with the Inveon Acquisi-
tion Workplace (Siemens Medical Solutions, Knoxville, 
TN, USA). 18F-FDG list-mode acquisitions were recon-
structed, as described previously [12].
PET image analysis
PET images were analyzed using the Inveon Research 
Workplace (Siemens Medical Solutions) as described 
previously [10, 20].
Inveon Research Workplace was used for assessing 
the percentage of the injected activity per gram (%IA/g) 
in the myocardium and left ventricular metabolic vol-
ume (LVMV) for the measurement of myocardial mass 
from static images. A cubic volume of interest (VOI) 
was drawn around the left ventricle, and a threshold 
value excluding the 30% least hottest voxels was applied. 
Correct VOI placement was always verified in three 
projections (axial, sagittal, and coronal) [13]. ECG trig-
ger signal accuracy was retrospectively verified using 
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in-house software programmed in MATLAB (The Math-
works, Natick, USA) [20], and heart rate during the scan 
was extracted.
Estimates for myocardial viability were calculated 
from static images as a percentage of the left ventricu-
lar surface area and automated volume measurements 
with QPS® (Cedars-Sinai, Los Angeles, CA, USA) using 
a normative database, as described previously [11, 22]. 
Left ventricular function parameters: EDV, ESV, the SV, 
and the EF, were calculated from ECG-gated images 
using QGS® (Cedars-Sinai, Los Angeles, CA, USA), as 
described previously [10, 12].
Statistical analysis
All results were expressed as means with standard devia-
tion. One-way and two-way ANOVA analysis with Tuk-
ey’s multiple comparisons, paired and unpaired Student’s 
t-tests were used where appropriate. For groups without 
normal distribution, the Wilcoxon signed-rank or the 
Mann–Whitney U test was applied. The differences were 
considered statistically significant at a P-value of 0.05.
Results
Increasing cardiac metabolic and ventricle volume in male 
mice in early to mid‑adulthood
Serial micro PET scans in male mice at different time 
points ranging from 10 weeks, 14 weeks, and 18 weeks of 
age were performed to evaluate age-dependent changes 
in the hearts. The LVMV, which serves as a surrogate 
marker of the heart muscle mass (Fig.  1a upper panel), 
slightly increased within the first four weeks without 
reaching statistical significance. After this initial trend 
from 10 to 14 weeks, the increase in LVMV reached the 
level of significance in male mice at 18 weeks (10 weeks 
old male vs 18 weeks old male, p = 0.025, Fig. 1b left, and 
Table  1). Concurrent, the %IA/g resembling metabolic 
processes in the heart, slightly decrease over the eight 
weeks of follow-up (10  weeks old male vs 18  weeks old 
male, p = 0.058, Fig. 1a lower panel and 1B right).
Of note, although myocardial 18F-FDG uptake showed 
slight inhomogeneity in male mice at 14  weeks, there 
could be detected no significant difference in 18F-FDG 
uptake between the groups (please see discussion). 
(10  weeks old vs 14  weeks old, p = 0.462, 10  weeks old 
vs 18 weeks old, p = 0.985, 14 weeks old vs 18 weeks old, 
p = 0.449, Additional file 1: Figure S1A left).
Functional cardiac analysis (Fig.  2a, b), showed an 
unchanged EDV (10 weeks old vs 18 weeks old, p = 0.242, 
Fig. 2c) while there was a constant increase in ESV over 
time (10 weeks old vs 14 weeks old, p = 0.013, 10 weeks 
old vs 18  weeks old, p = 0.006, Fig.  2c). While SV 
remained widely stable over eight weeks up (10  weeks 
old vs 14 weeks old: p = 0.648, 10 weeks old vs 18 weeks 
old: p = 0.788, 14  weeks old vs 18  weeks old: p = 0.923, 
Fig.  2c), there was a significant decrease in the EF% at 
eight weeks of follow up (10 weeks old vs 18 weeks old, 
p = 0.023, Fig.  2c). Already at 14  weeks of age, a strong 
tendency towards a reduced EF% could be detected 
(10 weeks old vs 14 weeks old, p = 0.052).
Summarizing these measurements, there was an age-
dependent increase in LVMV and parallel increasing ESV 
with stable SV in male mice, indicating that male heart 
displays ongoing cardiac growth after ten weeks of age.
Stable cardiac metabolic and volume equilibrium in female 
mice in early to mid‑adulthood
In the eight weeks of serial cardiac assessment, the female 
mice did not show any change in the LVMV (10  weeks 
old vs 14 weeks old: p = 0.285, 10 weeks old vs 18 weeks 
old: p = 0.105, 14  weeks old vs 18  weeks old: p = 0.838, 
Fig. 2c and Table 2). The %IA/g uptake was constant over 
time (10 weeks old vs 14 weeks old: p = 0.636, 10 weeks 
old vs 18 weeks old: p = 0.631, 14 weeks old vs 18 weeks 
old: p = 0.993, Fig. 2c).
Of note, the cardiac viability was not decreased or 
limited at any time point (10  weeks old vs 14  weeks 
old: p = 0.236, 10  weeks old vs 18  weeks old: p = 0.341, 
14 weeks old vs 18 weeks old: p > 0.999, Additional file 1: 
Figure S1 A right). Analysis of clinically relevant car-
diac function parameters did not show any statistically 
significant changes in EDV (10  weeks old vs 14  weeks 
old: p = 0.079, 10  weeks old vs 18  weeks old: p = 0.344, 
14 weeks old vs 18 weeks old: p = 0.073, Fig. 2c).
The ESV did not change after the first four weeks, but 
after eight weeks it was significantly decreased (10 weeks 
old vs 14 weeks old: p = 0.911, 10 weeks old vs 18 weeks 
old: p = 0.081, 14  weeks old vs 18  weeks old: p = 0.003, 
Fig. 2c).
Regarding the SV, there was an initial increase within 
the first four weeks of follow up, that was stable at eight 
weeks (10 weeks old vs 14 weeks old: p = 0.009, 10 weeks 
old vs 18 weeks old: p = 0.004, 14 weeks old vs 18 weeks 
old: p = 0.404, Fig. 2c). As a consequence of the rise in SV, 
the EF slightly increased over the time course of serial 
measurements (10 weeks old vs 14 weeks old: p = 0.588, 
10 weeks old vs 18 weeks old: p = 0.014, 14 weeks old vs 
18 weeks old: p = 0.032, Fig. 2c). Surprisingly, in contrast 
to male mice, there were no significant cardiac physiol-
ogy changes in female mice.
Gender‑specific alteration in cardiac function parameters 
over eight weeks of follow up
As compared to female mice, LVMV was significantly 
higher in male mice at 14 and 18 weeks of age (14 weeks 
























































































Fig. 1 Changes in LVMV and cardiac %IA/g in ageing mice. a Representative cardiac PET scan images for LVMV and %IA/g are illustrated. The upper 
panel shows the accumulation of 18F-FDG in the left ventricle in the coronal, the horizontal long axis and the vertical long axis. The lower panel 
of the left ventricle shows the VOI where the 30% least hottest voxels were excluded. b Shows the LVMV and cardiac %IA/g for male (in blue) and 
female mice (in red) at 10, 14 and 18 weeks of age. All groups n = 8. All data represent mean ± SD. * p = 0.05, ** p < 0.01, *** p < 0.001
Table 1 Multiparametric longitudinal PET measurements in male mice
LVMV left ventricular metabolic volume, EDV end-diastolic volume, ESV end-systolic volume, SV stroke volume, EF ejection fraction, %IA/g percentage of the injected 
activity per gram (determined within the VOI where the 30% least hottest voxels were excluded), bodyweight of the animals
Male mice LVMV EDV (µl) ESV (µl) SV (µl) EF (%) %IA/g Weight (g)
10 weeks old 200.0 ± 24.4 36.4 ± 7.6 6.4 ± 3.2 30.1 ± 7.0 82.4 ± 9.2 30.5 ± 7.1 24.7 ± 0.8
14 weeks old 224.4 ± 21.7 39.3 ± 4.1 12.5 ± 3.1 26.8 ± 4.8 68.0 ± 7.9 24.2 ± 6.4 26.6 ± 0.9
18 weeks old 226.0 ± 13.2 42.6 ± 5.3 15.0 ± 5.5 27.8 ± 6.4 65.0 ± 13.5 21.5 ± 4.9 28.4 ± 1.7
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old: male vs female, p = 0.012, 18  weeks old: male vs 
female, p = 0.003 Fig. 1b left).
Although there was a tendency in male mice towards a 
lower %IA/g over time, no significant difference between 
the sexes at the three-time points could be observed. 
(10  weeks old: male vs female, p = 0.839, 14  weeks old: 
male vs female, p = 0.969, 18 weeks old: male vs female, 
p = 0.098 Fig. 1b right).
While EDV over time displayed no gender-specific dif-
ferences (10 weeks old: male vs female, p = 0.935, 14 weeks 
old: male vs female, p = 0.754, 18  weeks old: male vs 
female, p = 0.935, Fig.  2c), there was a significant higher 
ESV in male compared to female mice at 18 weeks of age 
(18  weeks old: male vs female, p = 0.003, Fig.  2c), but no 
significant differences regarding SV at the different time 
points (10  weeks old: male vs female, p > 0.999, 14  weeks 
old: male vs female, p = 0.513, 18 weeks old: male vs female, 
p = 0.596, Fig.  2c). Nonetheless, a significant difference 
in EF% at 18  weeks of age between the genders could be 
observed. In contrast to their female counterparts, male 
mice showed a mean decreased EF by approximately 16% 
(18  weeks old: male vs female, p = 0.012, Fig.  2c). These 
findings strongly indicate that the male heart shows dis-
tinct cardiac concentric hypertrophy demonstrated by 
increasing LVMV, increasing ESV, and decreasing EF%. In 
contrast, female mice’s hearts have already reached a stable 
steady-state at ten weeks of age.
Bodyweight comparison in both sexes during follow up
Before each single PET scan, the mice’s body weight 
was determined. As a result of this the body weight 
at the serial scans in male (10  weeks old vs 14  weeks 
old, p = 0.012, 10  weeks old vs 18  weeks old, p < 0.001, 
14  weeks old vs 18  weeks old, p = 0.022, Additional 
file 1: Figure S1 B left) and female mice (10 weeks old vs 
14  weeks old, p < 0.001, 10  weeks old: vs 18  weeks old, 
p < 0.001, 14 weeks old vs 18 weeks old, p = 0.002, Addi-
tional file 1: Figure S1 B middle) steadily increased over 
time. In gender comparisons, the starting body weight 
in male mice was significantly higher than in the age-
matched female counterparts (10  weeks old: male vs 
female, p < 0.001), and the difference remained constant 
over the time course of the experiments (18  weeks old: 
male vs female p < 0.001, Additional file  1: Figure S1 A 
right). Interestingly, we could also detect a positive cor-
relation of the mice body weight of all animals (male 
and female mice at 10, 14 and 18 weeks of age) to LVMV 
(r = 0.6441, p < 0.001, Additional file 1: Figure S1 C).
ECG tracking of both genders showing reduced heart 
rates in male mice, correlations to the percentage injected 
activity in the heart and left ventricular metabolic volume
During the gated cardiac PET scan (further explana-
tion in the methodical section), ECG data were recorded 
(Fig. 3a). As a result of this female mice showed a stable 
and significantly higher heart rate per minute than their 
male counterparts (10 weeks old: female: 490.4 ± 28.9 vs 
male: 402.4 ± 36.5, p < 0.001, Fig.  3b). Furthermore, this 
difference was statistically stable after the 8th week of 
the follow up (18 weeks old: female: 453.7 ± 55.2 vs male: 
396.8 ± 35.2, p = 0.044, Fig. 3b).
Furthermore, heart rate showed strong, significant pos-
itive correlation with %IA/g (r = 0.518, p < 0.001, Fig.  3c 
left). In concordance to this observation, the LVMV dis-
plays a moderate but significant negative correlation the 
heart rate (r = −0.486, p < 0.001, Fig.  3c right). Of note, 
we could detect a statistically significant negative corre-
lation of the documented heart rate to the body weight 
(r = −0.549, p < 0.001, Additional file 1: Figure S1 D).
Discussion
In this study, we provide evidence for age-dependent 
gender-specific differences in murine hearts by small-
animal PET imaging.
By primarily assessing the left ventricular metabolic 
volume, we used a standardized method that provides 
an efficient and proven surrogate marker of murine 
heart mass [13]. Our results indicate that male hearts 
compared to female hearts are bigger in LVMV and that 
growth of male hearts continues after ten weeks of age. 
Here we show that the female heart increases only mildly 
and not statistically significant in the LVMV. Our results 
mirror human data showing that males’ heart mass is 
up to 15–30% higher [23]. It is known as well that male 
and female hearts show hypertrophy during ageing [24]. 
Yet our study did only document the murine early to 
mid-adulthood.
Regarding the clinically relevant cardiac parameters, 
the ESV in male increases over time. The SV remains sta-
ble, which is in line with the observation of growing male 
hearts [24]. While the male hearts could become more 
(See figure on next page.)
Fig. 2 Assessment of clinically relevant cardiac function parameters by three-dimensional PET imaging. a shows different PET images’ axes at 
various left ventricle levels during end-systole (left) and end-diastole (right). b illustrates three-dimensional reconstruction of the left ventricle in 
the ROA view. Upper picture: in end-systole and lower picture in end-diastole. c Comparison of male and female mice cardiac PET parameters at 
different stages of follow up. Data of male mice are illustrated in blue, and female mice are in red. All groups n = 7–8. Data represent mean ± SD. * 
p < 0.05, ** p < 0.01, *** p < 0.001
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Table 2 Multiparametric longitudinal PET measurements in female mice
LVMV left ventricular metabolic volume, EDV end-diastolic volume, ESV end-systolic volume, SV sstroke volume, EF ejection fraction, %IA/g percentage of the injected 
activity per gram (determined within the VOI where the30% least hottest voxels were excluded), bodyweight of the animals
Female mice LVMV EDV (µl) ESV (µl) SV (µl) EF (%) %IA/g Weight (g)
10 weeks old 181.1 ± 10.2 38.5 ± 1.9 10.1 ± 2.2 28.1 ± 2.0 73.3 ± 4.8 37.0 ± 7.2 20.7 ± 0.5
14 weeks old 193.0 ± 13.6 42.4 ± 2.9 10.6 ± 3.5 31.7 ± 1.9 75.1 ± 6.3 33.5 ± 7.0 24.0 ± 0.7
18 weeks old 189.3 ± 7.3 40.3 ± 1.6 7.3 ± 1.2 32.7 ± 1.6 81.5 ± 2.9 33.8 ± 5.0 25.4 ± 0.7
a
b








































































Fig. 3 ECG analysis in both genders. a depicts the ECG tracking during the PET scan. Small black crosses in the QRS complex demonstrate the time 
of the trigger event. b ECG assessment of the heart rate in both genders during the PET scans. c Correlation of heart rate with cardiac LVMV and 
%IA/g, respectively. All groups n = 7–8 at different time points and cumulative group size in correlations n = 45. All data represent mean ± SD. * p 
< 0.05, ** p < 0.01, *** p < 0.001.
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durable, they are in theory, not dependent on the former 
ventricle volume to maintain the body perfusion. There-
fore, as a consequence, the ejection fraction in male mice 
would drop. While the female hearts do not increase in 
LVMV at these stages of age, body mass increases over 
time. They could depend on more ESV reserve, and 
therefore, the EF% could increase for adequate organ 
perfusion.
The %IA/g, also described as %ID/g in previous pub-
lications resembles the ratio between the activity of the 
tracer detected in the tissue, and the total tracer activity 
injected [14, 19, 25]. Interestingly, the %IA/g in male mice 
tends to decrease over follow-up time. In contrast, the 
cardiac %IA/g remains stable in the female mice, which 
could be partially attributed to the moderate increase in 
body weight and the constant cardiac mass. Interestingly, 
our data indicate a positive correlation of %IA/g and the 
measured heart rate, which could illustrate a higher car-
diac demand for glucose at higher heart rates. However, 
the %IA/g could depend on multiple distinct and yet 
undetermined variables masking a direct affiliation.
Of note, the term %ID/g or more precisely %IA/g was 
primarily described in post-myocardial injury studies.
These recent studies could demonstrate that the car-
diac %IA/g in myocardial infarction is elevated in the 
acute phase on day five in humans [25]. This increased 
accumulation could be associated with the inflammatory 
response, and the invading immune cells and subsequent 
higher glucose consumption in the tissue [11, 14]. Herein, 
we could demonstrate that the uptake of 18F-FDG also 
positively correlates with murine heart rate. Our results 
also support the notion that increasing heart mass in 
healthy hearts, represented by LVMV, correlates with 
reduced heart rates. The documented murine heart rate 
and correlation towards the cardiac surrogate marker 
LVMV, even with isoflurane narcotic, is in line with pub-
lished studies [26][27]. Of note, we cannot exclude sex 
differences in response to anaesthesia, since the standard 
mouse model is male and more research is warranted to 
provide insight.
A limitation of the 18F-FDG PET scan could be the 
usage of isoflurane, as discussed in [16]. Concerning the 
usage of 18F-FDG, cardiac uptake and metabolism could 
be modified by various systemic factors, e.g., insulin and 
glucagon that were not evaluated in this study [17].
This study provides insight into the cardiac homeosta-
sis at 10 weeks, 14 weeks, and 18 weeks of age in male and 
female mice using the innovative design of serial non-
invasive PET imaging. Our results could help research 
groups determine the correct age choice for their murine 
injury model in both sexes and avoid growth-related 
biases.
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